If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). This serious brain infection, while rare, requires awareness and monitoring. The medical community's understanding of this risk has evolved through years of clinical observation and research, providing a foundation for informed discussions between patients and healthcare providers. This page outlines the key facts about Tysabri and PML, including symptoms, risk factors, and monitoring strategies.
Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, specifically highlighting the increased risk of PML. The clinical presentation of PML is variable and can include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and visual changes. A retrospective national cohort study of 456 Italian PML patients observed between 1987 and 2024 described the demographic, clinical, radiological, and laboratory characteristics of the disease, noting that PML is a severe demyelinating condition affecting immunocompromised individuals (https://pubmed.ncbi.nlm.nih.gov/40922664/). Diagnosis typically relies on brain MRI findings and detection of JCV DNA in cerebrospinal fluid, though clinical suspicion is paramount.
The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammatory activity in conditions like multiple sclerosis but also impairs normal immune surveillance within the brain. Under these conditions, latent JCV can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri dosing immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This program is designed to ensure that patients are informed of the risks and that appropriate monitoring occurs. However, despite these measures, adverse events continue to be reported. FDA FAERS adverse-event reports most frequently associated with Tysabri include fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), and gait disturbance (9,422 reports), among others (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not establish causation, they reflect the real-world experience of patients using the drug.
The adequacy of warnings regarding Tysabri and PML is a critical consideration. The boxed warning explicitly states that Tysabri increases the risk of PML and that it usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). It also identifies the three known risk factors and instructs healthcare professionals to monitor patients and withhold Tysabri at the first sign of PML. However, questions may arise about whether patients and providers fully understand the magnitude of risk, the subtlety of early PML symptoms, and the importance of prompt action. The TOUCH program is intended to address these issues, but its effectiveness in preventing harm depends on rigorous adherence and patient education. For patients who develop PML after Tysabri exposure, the timeline between drug initiation and symptom onset is variable. The risk increases with longer treatment duration, particularly beyond two years, but cases have been reported earlier, especially in patients with additional risk factors such as anti-JCV antibodies or prior immunosuppressant use. The clinical course of PML can be rapid, and early diagnosis is crucial because treatment options are limited and primarily supportive. Once PML is suspected, Tysabri should be discontinued immediately, and plasma exchange may be considered to accelerate drug clearance. Attorney-related considerations for affected patients are significant. Patients who develop PML after Tysabri therapy may face substantial medical costs, long-term disability, and loss of quality of life. Legal claims may focus on whether the drug manufacturer provided adequate warnings about PML risk, whether the TOUCH program was properly implemented, and whether healthcare providers followed appropriate monitoring protocols. In Pennsylvania, as in other states, product liability law allows patients to seek compensation for injuries caused by defective drugs, including failure to warn claims. An experienced Tysabri PML injury lawyer can help evaluate the specific circumstances of a case, including the patient's risk factors, the duration of Tysabri therapy, and the timing of symptom onset relative to treatment.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA has issued a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Three key risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially over two years), and prior use of immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Patients may pursue product liability claims, including failure to warn, against the manufacturer. An experienced Tysabri PML injury lawyer can evaluate the case based on risk factors, treatment duration, and timing of symptoms.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.